19 reports

Global Market Study on Rare Endocrine Disease Treatment: Appropriate Treatment Evaluation and Research Collaborations to Drive Treatment Developments during 2017-2026 ##.

  • Endocrine Disease
  • Therapy
  • World
  • Market Shares
  • Market Size
  • Hypothyroidism Trial Snapshots- 2013
  • Hypothyroidism Trial Snapshots- 2013

Hypothyroidism is a thyroid disorder where thyroid gland secretes less triiodothyronine (T3) and thyroxine (T4) inadequate to meet peripheral tissue demand. To compensate the decline in T3 and T4 levels, thyroid stimulating hormone (TSH) is produced in the pituitary gland. These hormones regulate metabolism in the body and irregular...

  • Endocrine Disease
  • Eastern Mediterranean
  • Europe
  • World
  • Company Operations
  • APR 26, 2017: SHIRE GRANTED EU CONDITIONAL MARKETING AUTHORISATION FOR NATPAR (PARATHYROID HORMONE) FOR THE TREATMENT OF PATIENTS WITH CHRONIC HYPOPARATHYROIDISM
  • MAY 19, 2017: SHIRE TO HIGHLIGHT NEW RESEARCH INTO CHRONIC HYPOPARATHYROIDISM AT THE EUROPEAN CONGRESS OF ENDOCRINOLOGY

Hypoparathyroidism is a rare endocrine disease resulting from an inappropriately low circulating PTH concentration.

  • Endocrine Disease
  • European Union
  • United States
  • World
  • Product Initiative

This agreement enables PeptiDream and Ipsen to discover, develop and commercialize therapeutic peptides to treat serious Endocrine diseases.

  • Endocrine Disease
  • United States
  • Company Financials
  • Demand
  • Ipsen S.A.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

Hashimoto Thyroiditis Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Hashimoto Thyroiditis Global Clinical Trials Review, H2, 2017" provides an overview of Hashimoto Thyroiditis clinical trials scenario. This report provides top line data relating to the clinical trials on Hashimoto...

  • Endocrine Disease
  • Pathology
  • Therapy
  • World
  • Product Initiative
  • MAR 12, 2018: SHIRE TO HIGHLIGHT ADVANCEMENTS IN CHRONIC HYPOPARATHYROIDISM RESEARCH AT THE ENDOCRINE SOCIETY'S 2018 ANNUAL MEETING
  • APR 26, 2017: SHIRE GRANTED EU CONDITIONAL MARKETING AUTHORISATION FOR NATPAR (PARATHYROID HORMONE) FOR THE TREATMENT OF PATIENTS WITH CHRONIC HYPOPARATHYROIDISM

MAR ##, 2018: NEW DATA PRESENTED AT THE ENDOCRINE SOCIETY' S 2018 ANNUAL MEETING ADVANCES UNDERSTANDING OF THE RARE DISEASE CHRONIC HYPOPARATHYROIDISM Shire plc, the global leader in rare diseases, announced new data on its recombinant human parathyroid hormone (

  • Endocrine Disease
  • Europe
  • United States
  • World
  • Product Initiative
  • Hyperthyroidism Trial Snapshots- 2012

One trial entered phase ##.

  • Drug Discovery And Development
  • Endocrine Disease
  • World
  • Company Operations
  • Product Initiative
  • Hypothyroidism - Companies Involved in Therapeutics Development
  • Hypothyroidism - Pipeline by Synthonics Inc, H1 2018

Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease.

  • Endocrine Disease
  • Hormone
  • Therapy
  • World
  • Product Initiative
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

CARDIOMETABOLIC DISEASE THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2017* CARDIOMETABOLIC DISEASE THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2017* CARDIOMETABOLIC DISEASE THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, ##

  • Endocrine Disease
  • Pathology
  • World
  • Product Initiative
  • 06/21/2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly

Poster Presentations: Oct ##, 2017: Crinetics Pharmaceuticals Initiates Phase ## Study of Lead Candidate CRN## for Acromegaly Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, annou

  • Endocrine Disease
  • United States
  • Company
  • Corporate Finance
  • Crinetics Pharmaceuticals, Inc.
  • 06/21/2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly

Poster Presentations: Oct ##, 2017: Crinetics Pharmaceuticals Initiates Phase ## Study of Lead Candidate CRN## for Acromegaly Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, annou

  • Endocrine Disease
  • United States
  • Company
  • Corporate Finance
  • Crinetics Pharmaceuticals, Inc.
  • 06/21/2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly

Poster Presentations: Oct ##, 2017: Crinetics Pharmaceuticals Initiates Phase ## Study of Lead Candidate CRN## for Acromegaly Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, annou

  • Endocrine Disease
  • United States
  • Company
  • Corporate Finance
  • Crinetics Pharmaceuticals, Inc.

The company' s submission of abemaciclib includes two indications: abemaciclib monotherapy for patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor ##-negative (HER##-) advanced breast cancer who had prior endocrine therapy and chemotherapy for metastatic

  • Clinical Trial
  • Endocrine Disease
  • Healthcare
  • Insulin Delivery
  • Sanofi S.A.

Radius Health, Inc., a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that additional positive results from the Phase ## ACTIVE (Abaloparatide Comparator Trial

  • Endocrine Disease
  • Hormone
  • Musculoskeletal Disorder
  • Therapy
  • World

Radius Health, Inc., a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, presented results from " Response Rates for Hip, Femoral Neck, and Lumbar Spi

  • Drug Discovery And Development
  • Endocrine Disease
  • Musculoskeletal Disorder
  • Pharmaceutical
  • World

ENDOCRINE HORMONES: THE PRODUCTS SECRETED BY THE ENDOCRINE GLANDS.

  • Endocrine Disease
  • United States
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Takeda Pharmaceutical Company Limited
  • 4.1 DISEASE BACKGROUND

ENDOCRINE PRACTICE; ##(##): ##-##.

  • Endocrine Disease
  • Forecast
  • Amgen Inc.
  • Keryx Biopharmaceuticals, Inc.
  • OPKO Health, Inc.
  • 2.1 DISEASE BACKGROUND

Endocrine Connections; ##(##): ##-##.

  • Endocrine Disease
  • Japan
  • United Kingdom
  • United States
  • Forecast
  • XOMA Corporation - Company Statement

Our business efforts are focused on advancing the assets in our portfolio of compounds that could treat a variety of endocrine diseases.

  • Endocrine Disease
  • Therapy
  • United States
  • Company Operations
  • XOMA Corporation